# The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

> **NCT07241169** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhongshan Ophthalmic Center, Sun Yat-sen University** · enrollment: 9 (estimated)

## Conditions studied

- Stargardt

## Interventions

- **DRUG:** ZVS106e

## Key facts

- **NCT ID:** NCT07241169
- **Lead sponsor:** Zhongshan Ophthalmic Center, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-29
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241169, "The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07241169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*